LA JOLLA PHARMACEUTICAL CO (LJPC)
US5034596040 - Common Stock
Innoviva Completes Acquisition of La Jolla Pharmaceutical
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
SHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
SHAREHOLDER ALERT: Weiss Law Reminds LJPC, CNVY, ACC, and MN Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, LJPC, FSI, SYRS
/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Investigates La Jolla Pharmaceutical Company
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of La Jolla Pharmaceutical...
5 Top Short Squeeze Stocks to Watch This Week
It's a new week and that means it's time to check in on all of the short squeeze stocks that traders need to keep an eye on!
La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News
A headline-grabbing takeover deal could be impactful for the medical community - and today, it's definitely huge news for LJPC stock holders.
Innoviva to Acquire La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress
La Jolla Pharmaceutical Company Announces Share Repurchase Plan
La Jolla Pharmaceutical (LJPC) Reports Q3 Loss, Tops Revenue Estimates
La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of -14.29% and 10.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tony Hodges, M.D., FACP, FCCP, Appointed Chief Medical Officer of La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Corporate Progress
A Trigger to Get Long: Three Inside Up, RSI, Moving Average Trigger in La Jolla Pharmaceutical Co
The Techncial Trigger Driven Stock Trade in La Jolla Pharmaceutical Co (NASDAQ:LJPC) .